24 results about "Bacterial antigen" patented technology

A construction and use of an environmentally adaptive co-regulated mRNA nanodelivery system. By incorporating EACR molecules into mRNA nanoparticles, the microenvironment is remodeled to be suitable for robust and sustained mRNA expression, while tissue damage associated with the self-immunogenicity of mRNA drugs is avoided. The nanodelivery system is compatible with ionizable lipid nanoparticles, cationic liposomes, cationic nanoemulsions, and polymeric nanoparticles. The EACR molecules include: anti-inflammatory drugs, tyrosine kinases / adaptors, JAK / STAT and MAPK pathway inhibitors, nutrients and metabolites, membrane transporters / ion channels, phosphodiesterase and cellular stress inhibitors, and natural viral proteins. The therapeutic mRNAs may encode tumor, viral, or bacterial antigens, immunomodulatory factors, therapeutic antibodies, or functional proteins / enzymes, and can play a role in the fields of regenerative medicine, protein supplementation / replacement therapy, targeted gene editing, and immunotherapy.

The invention discloses preparation and application of micromolecular coated oncolytic bacteria, and relates to the field of nano-drugs. According to the coated bacteria, the surface of attenuated salmonella VNP20009 is coated with a nano-coating formed by coordination of micantrone and calcium ions, a bacterial antigen signal is shielded, so that the peripheral clearance rate and toxicity risk of the attenuated salmonella VNP20009 in blood circulation are reduced, and the coated bacteria have good biocompatibility and can maintain natural physiological characteristics and biodegradability of the bacteria. In order to solve the problems of lack of effective molecular targets and high immunosuppression of triple negative breast cancer (TNBC), the coated oncolytic bacteria utilize the natural tropism of VNP20009 on TNBC and the physiological targeting motion characteristic to directionally deliver miltroquinone and calcium ions, and cooperate with the oncolytic bacteria to kill tumor cells; bacterial surface antigen signals are shielded, so that tumor accumulation is increased, peripheral toxicity is avoided, and a breakthrough is provided for overcoming long-term failure of oncolytic bacteria clinical tests.

The object of the present invention is to provide an active ingredient for a systemically administered mRNA pharmaceutical that expresses an antibody specific to the V antigen protein or its homologous protein of Gram-negative bacteria, and a systemically administered mRNA pharmaceutical using the same. [Solution] mRNA containing an antibody coding region encoding a specific scFv antibody against the V antigen protein or its homologous protein of pathogenic Gram-negative bacteria is useful as an active ingredient in mRNA pharmaceuticals for systemic administration.

Disclosed are methods, systems, components, and compositions for cell-free synthesis of glycosylated carrier proteins. The glycosylated carrier proteins may be utilized in vaccines, including anti-bacterial vaccines. The glycosylated carrier proteins may include a bacterial polysaccharide conjugated to a carrier, which may be utilized to generate an immune response in an immunized host against the polysaccharide conjugated to the carrier. The glycosylated carrier proteins may be synthesized in cell-free glycoprotein synthesis (CFGpS) systems using prokaryote cell lysates that are enriched in components for glycoprotein synthesis such as oligosaccharyltransferases (OSTs) and lipid-linked oligosaccharides (LLOs) including OSTs and LLOs associated with synthesis of bacterial O antigens.

The present invention provides multispecific antigen-binding molecules that bind both a T cell antigen (e.g., CD3) and a target antigen (e.g., a tumor-associated antigen, a viral or bacterial antigen), and which comprise a single polypeptide chain that is multivalent (e.g., bivalent) with respect to T cell antigen binding, and uses thereof.

The present invention relates to an in-vitro diagnosis device for detecting and / or identifying antigen and / or antibody from a sample of biological fluid, particularly from a sample of blood or sample of blood components. The invention also relates to different uses of this device such as the detection and / or the identification of red blood cells antigens, platelet antigens, viral antigens, bacterial antigens, parasite antigens, the detection and / or the identification of anti-red blood cells antibodies, antiplatelet antibodies, antiviral antibodies, antibacterial antibodies and antiparasitic antibodies.

The present disclosure provides novel outer membrane vesicles (OMVs) comprising selective bacterial antigens (e.g., glycan antigens and / or protein antigens), use of such OMVs as vaccines (e.g., vaccines against N. gonorrhoeae) to protect against infectious diseases, and methods of making the same. The present disclosure also provides genetically engineered Escherichia coli for producing the OMVs and methods of making the same.

The invention provides attenuated salmonella typhimurium and application thereof, and the provided attenuated salmonella typhimurium is prepared by knocking out a relA gene, a manA gene and a sifA gene. According to the three-gene salmonella attenuated strain provided by the invention, an antigen is presented to a host cell through oral immunization, so that an organism is induced to generate immune response. The action mechanism of the salmonella as the live vector is that after carrying bacterial antigens to pass through intestinal epithelium, the bacterial antigens are transferred to immune cells through intestinal mucosa, and the immune response of a host is triggered. Safety detection shows that the attenuated strain constructed by the invention is high in safety, and can be used as a carrier to carry other pathogenic antigens or drugs to an action site so as to play a role of the carrier.

The present invention relates to a combination therapy against pathogenic bacteria in the gut, wherein a bacteriophage against the capsule of the pathogenic bacterium is combined with a vaccination against a bacterial antigen which is normally masked by the capsule.

Disclosed are methods, systems, components, and compositions for cell-free synthesis of glycosylated proteins. The glycosylated proteins may be utilized in vaccines, including anti-bacterial vaccines. The glycosylated proteins may include a bacterial polysaccharide conjugated to a carrier, which may be utilized to generate an immune response in an immunized host against the polysaccharide conjugated to the carrier. The glycosylated proteins may be synthesized in cell-free glycoprotein synthesis (CFGpS) systems using prokaryote cell lysates that are enriched in components for glycoprotein synthesis such as oligosaccharyltransferases (OSTs) and lipid-linked oligosaccharides (LLOs) including OSTs and LLOs associated with synthesis of bacterial O antigens.

The invention belongs to the technical field of veterinary biology, and discloses an escherichia coli NK2 strain and application thereof in preparation of a mycoplasma hyopneumoniae culture medium. According to the invention, an Escherichia coli NK2 is screened, and the preservation number of the Escherichia coli NK2 is CCTCC (China Center For Type Culture Collection) NO: M20252722. The mycoplasma hyopneumoniae high-efficiency culture medium is prepared by the applicant by taking fermentation supernate of an endotoxin-removed escherichia coli NK2 strain as an auxiliary culture medium, the growth speed of the mycoplasma hyopneumoniae can be increased by adding the auxiliary culture medium, the culture time of the mycoplasma hyopneumoniae can be shortened, and the yield of the mycoplasma hyopneumoniae can be increased. Therefore, generation of aged bacteria is reduced, the viable count during culture harvesting is remarkably increased, the thallus antigen content during culture harvesting is remarkably improved, and the method has the advantages of being convenient to use, easy to obtain, low in cost, high in economic benefit and the like.

The present invention relates to an in vitro diagnostic device for detecting and / or identifying antigens and / or antibodies from a biological fluid sample, in particular from a blood sample or a blood component sample. The present invention also relates to different uses of the device, such as detecting and / or identifying red blood cell antigens, platelet antigens, viral antigens, bacterial antigens, parasite antigens, detecting and / or identifying anti-red blood cell antibodies, anti-platelet antibodies, anti-viral antibodies, anti-bacterial antibodies and anti-parasite antibodies.

The present invention relates to a recombinant yeast cell genetically modified to express (i) at least one first bacterial antigen or an immunogenic fragment thereof intracellularly and (ii) at least one second bacterial antigen or an immunogenic fragment thereof on its extracellular surface, the at least one first bacterial antigen or an immunogenic fragment thereof being identical to or different from the at least one second bacterial antigen or an immunogenic fragment thereof. The present invention also concerns this recombinant yeast for use in vaccines and in treating or preventing bacteria-caused pathologies in livestock.

The invention discloses a bacterial holoantigen-loaded PLGA (poly (lactic-co-glycolic acid)) microsphere vaccine as well as a preparation method and application thereof. The method comprises the following steps: cracking target bacteria by adopting a bacterial cell protein lysis solution to obtain whole-bacterial antigens, and preparing whole-bacterial antigen particles in a nanoparticle form in a high-pressure co-extrusion manner; the antigen particles and a PLGA microsphere carrier are mixed through a multiple emulsion method, and a microsphere vaccine (MSV) with antigens loaded inside and outside the carrier can be obtained. The antigen on the surface of the MSV is released in a burst release manner, and the antigen loaded in the MSV can achieve a long-acting slow release effect, so that the programmed step-by-step release control of the antigen release behavior is realized, that is, the dual effects of primary immunization and enhanced immunization can be achieved by single-dose vaccine injection. In addition, the MSV can effectively avoid damage of bacterial toxins to immune cells of the body, and the biological safety of bacterial vaccines is improved. The design is reasonable, and the introduction of the microsphere preparation provides a safe and reliable carrier platform for a bacterial inactivated vaccine.

This invention belongs to the field of catalytic materials technology, specifically relating to a porous carbon biocatalytic material loaded with rhodium-iron bimetallic active sites, its preparation method, and its applications. The porous carbon biocatalytic material comprises a spiky porous carbon substrate, and rhodium clusters and iron single atoms uniformly loaded on its surface, forming Rh-Fe bimetallic active sites with charge transfer effects. The porous carbon biocatalytic material of this invention exhibits peroxidase-like and NADH oxidase-like activities under acidic conditions, and glucose oxidase-like, catalase-like, and superoxide dismutase-like activities under neutral conditions. It can efficiently kill bacteria and adsorb bacterial antigens, preventing macrophages from excessively polarizing to a pro-inflammatory state, ultimately promoting tissue regeneration and achieving ultra-rapid healing of inflammatory diabetic ulcers, with good biocompatibility.

The invention relates to a new topical nasal pharmaceutical composition for the treatment and prophylaxis of Rhinosinusitis (RS), comprising a homogeneous aqueous suspension with a therapeutically effective amount of the following well-known active ingredients: Rifamycin, an antibiotic and anti-inflammatory agent for topical or local use; fluticasone propionate, an anti-inflammatory agent for local use; optionally, oxymetazoline hydrochloride, a decongestant; and bacterial antigens, local immunostimulants; 0.9% saline solution, a vehicle; and pharmaceutically acceptable excipients q.s., which are formulated for topical administration via nasal spray. The combination of these compounds produces synergy, resulting in a greater local antibiotic, anti-inflammatory, decongestant and immunomodulatory effect at the specific site of action. Its effectiveness in chronic rhinosinusitis is particularly notable in low doses. So is its good tolerance, absence of adverse effects, and ease of application. No rebound congestion has been reported with prolonged use.

The present invention is based on the discovery of new and advantageous properties of a class of known polymeric emulsifiers. The emulsifier class was found to be resistant to degradation by crude bacterial antigen preparations, which degradation caused emulsion instability when using prior art emulsifiers. This allows the formulation of safe, stable, and effective vaccines based on these emulsions of oil and water comprising such bacterial antigens. The polymeric emulsifier is a block copolymer having a general formula A-B-A in which component B is the divalent residue of a water-soluble polyalkylene glycol and component A is the residue of an oil-soluble complex monocarboxylic acid. Preferred emulsifier is a PEG-30-di-(polyhydroxystearate).

The invention discloses a vaccine composition which comprises a bacterial antigen and at least one drug carrier, the drug carrier is a saponin-containing polymer microsphere which is formed by freezing and thawing a polymer microsphere with a cavity structure so as to form an opening or a pore on the surface of the polymer microsphere, the preparation method of the vaccine composition comprises the following steps: mixing the drug carrier with a solution containing bacterial antigens, preferably enabling the bacterial antigens to be loaded on the drug carrier in modes of infiltration and / or adsorption and the like, and then centrifuging to remove supernate so as to obtain the polymer microspheres loaded with the antigens.

The invention relates to the technical field of mycoplasma hyopneumoniae detection, and particularly discloses a mycoplasma hyopneumoniae antibody detection kit which comprises a magnetic particle coating antigen, an acridinium ester labeled antibody, a standard substance, a quality control substance, a pre-excitation solution, an excitation solution and a washing solution. According to the invention, the recombinant P97CR1 protein is adopted as a coating antigen, and a double-antibody sandwich method is combined, so that the detection specificity is greatly enhanced, and the cross reaction interference of genetic pathogens is effectively eliminated; the problem that the false positive rate of traditional whole-cell antigen detection is high is solved, meanwhile, the antigen coating efficiency is improved through polydopamine (PDA) modified magnetic particles, a pre-excitation liquid / excitation liquid system composed of fluoboric acid and sodium hydroxide is adopted, the detection sensitivity is greatly improved, and the defect that an existing method cannot meet early diagnosis is overcome.

The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a bacterial antigen selected from a lipoteichoic acid (LTA); a glucosaminidase (Gmd); a clumping factor A (ClfA); a Staphylococcus Protein A (SpA); an alpha toxin; a leukocidin; a gamma toxin; or a Sbi. The antigen can be an antigen that is expressed by Staphylococci (e.g., S. aureus) and, in certain embodiments, by one or more other bacteria. Also provided are polynucleotides that encode an antibody or antigen-binding fragment, vectors that comprise such polynucleotides, host cells that can express the antibodies, related compositions, and methods of using the herein disclosed compositions to, for example, treat or prevent a bacterial infection.

Bacterial antigen presenting cells are provided. Fusion proteins comprising a peptide-MHC complex, linker, and an autotransporter can be expressed on the surface of gram-negative bacteria, which can selectively stimulate T-cells reactive to the peptide-MHC complex. The bacterial antigen presenting cells can be used, e.g., to stimulate T-cells in vitro or in vivo.

The invention provides a human mycoplasma pneumoniae inactivated vaccine preparation and application thereof. The human mycoplasma pneumoniae inactivated vaccine preparation comprises inactivated mycoplasma pneumoniae thallus antigens and mucous membrane adjuvants. Wherein the mass ratio of the inactivated mycoplasma pneumoniae thallus antigen to the mucous membrane adjuvant is (2-5): 1. The inactivated vaccine preparation disclosed by the invention can induce an organism to generate mycoplasma pneumoniae specific IgG and IgA antibody titers after immunization in a nasal drop way, can protect the organism after mycoplasma pneumoniae infection, avoids weight loss and severe lung injury, fills the blank in the field of mycoplasma pneumoniae vaccines, and meets clinical requirements.

The present invention discloses a Staphylococcus aureus β-hemolysin antigen epitope polypeptide and a monoclonal antibody against the epitope, wherein the amino acid sequences of the heavy chain variable region and the light chain variable region of the monoclonal antibody are shown in SEQ ID NO.1 and SEQ ID NO.2. The present invention also discloses a kit for detecting Staphylococcus aureus β-hemolysin, wherein the kit comprises an effective amount of monoclonal antibody, Staphylococcus aureus β-hemolysin mutant protein, Staphylococcus aureus β-hemolysin mutant protein polyclonal antibody and matching detection reagents. The antigen epitope polypeptide prepared by the present invention has good immunogenicity and specificity; the monoclonal antibody prepared by the present invention has good specificity and sensitivity; the diagnostic kit prepared using the monoclonal antibody of the present invention has good specificity, sensitivity and accuracy.